AMED Ventures
VC Fund
San Francisco, United States
AMED Ventures is a VC fund in San Francisco focused on Health Care and Medical Device. AMED Ventures
- Total investments:
- 22
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries AMED Ventures invests in
Stages AMED Ventures invests in
Countries AMED Ventures invests in
Investment Focus
Industry
- Health Care 11 (50%)
- Medical Device 9 (41%)
- Medical 8 (36%)
- Biotechnology 5 (23%)
- Training 1 (5%)
Stage
- Series B 6 (27%)
- Series C 5 (23%)
- Venture - Series Unknown 4 (18%)
- Series E 3 (14%)
- Series A 2 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rejoni
|
Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $25M / Venture - Series Unknown / Jun 16, 2026 | |
Kandu Health
|
Kandu Health is a tech-enabled healthcare company that provides stroke recovery training, stroke detection research, and education services. | $30M / Venture - Series Unknown / Apr 08, 2025 | |
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $120M / Series E / Mar 26, 2025 | |
Imperative Care
|
Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $150M / Series E / Jul 25, 2024 | |
Adona Medical
|
Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options andenable providers to improve care for heart failure patients. | $33.5M / Series C / Jul 10, 2024 | |
|
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $40M / Series D / Nov 21, 2023 | |
Akura Medical
|
Akura Medical offers products and services centered on mechanical thrombectomy and imaging software for venous thromboembolism treatment. Its Katana Thrombectomy System uses a steerable catheter with integrated jet-based technology to access clot material, break it down, and support clot removal during a procedure. The system provides proceduralfeedback intended to help clinicians assess clot engagement and clearance while operating the device. Akura Medical also develops NavIQ, a software tool that transforms CT angiograms into 3D vascular models that display clot location and morphology to guide procedural planning. Together, these products form a workflow that supports physicians from pre-procedure assessment through clot extraction in cases involving pulmonary embolism and related VTE conditions. | $35M / Series B / Oct 03, 2023 | |
Instylla
|
Instylla’s focus is to leverage hydrogel technology . | $30M / Series C / Aug 15, 2023 | |
Sealonix
|
Sealonix focuses on the development and commercialization of hemostatic sealants using its proprietary biomaterials. Sealonix is working on a sealant patch that will provide quick hemostasis for abdominopelvic and orthopedic operations. The PramStat patch is intended to bioabsorb within one week of implantation. | $20M / Series A / May 12, 2023 | |
Tioga Cardiovascular
|
Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach. | $30M / Series C / Feb 09, 2023 | |
| See all 22 investments → | |||
Co-Investors
Cormorant Asset Management
11 deals together
The Capital Partnership
9 deals together
Excelestar Ventures
6 deals together
Shifamed
6 deals together
Ascension Ventures
5 deals together
Sparta Group
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does AMED Ventures invest in?
AMED Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series C stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did AMED Ventures last invest?
The most recent investment recorded for AMED Ventures closed in Jun 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
